Skip to main content
Caplight Logo









iMEAN

iMEAN

Private
ToulouseHealthcare & Life Scienceshttps://imean-biotech.com/

Last Round

Grant

Jul 9, 2020

Company Overview

iMEAN is a biotechnology company that provides R&D support services using digital organisms and mathematical modeling for the agriculture, industrial biotechnology, and healthcare sectors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

digital organismsin silico modelingorganism designbioinformatics platformdigital twin for biologysynthetic biologygenome-scale modelingbioprocess optimizationmetabolic engineeringsynbiocomputational biologyindustrial biotechnologyagricultural biotechnologysystems biologyomics data integrationR&D services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iMEAN Comparables

Compare iMEAN with similar companies based on industry and business-model similarity.

iMEAN comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Yokogawa Electric Corporation
73%
Differential Bio
72%
New Wave Biotech
69%

iMEAN Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 9, 2020
AcceleratorSep 3, 2018

Key People

Founding team and executive leadership

Lucas Marmiesse

Co-founder, Directeur Général, CTO

Founding Team

Rémi Peyraud

CEO

Executive Team

iMEAN Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 25, 2026

    Grew 18% QoQ, from 17 to 20 employees.

  • Jul 9, 2020

    Received grant funding from Bpifrance and other French entities.

iMEAN Filings

Explore SEC and related filing metadata, where available.

iMEAN filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about iMEAN's valuation, stock price, and market status.

Is iMEAN a public or private company?

iMEAN is a private company.

What is the current stock price of iMEAN?

iMEAN is a private company with no public stock price. No recent secondary market data is available.

How much is iMEAN worth (valuation)?

Valuation information for iMEAN is not publicly available.

Can I buy iMEAN stock?

iMEAN shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was iMEAN's last funding round?

iMEAN's most recent funding round was Grant on July 9, 2020.

Who are the main investors in iMEAN?

Key investors in iMEAN include Région Occitanie, French Ministry of the Economy, Finance and Industrial and Digital Sovereignty, Bpifrance, Nubbo.

Will iMEAN IPO soon?

No public IPO plans have been announced for iMEAN.

How can I track iMEAN secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iMEAN's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersToulouse
Employee Range15
Year Founded2018
Last FundingJul 9, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?